Health Care · In Vitro & In Vivo Diagnostic Substances

NTLA Intellia Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1652130107 filings
Russell 2000

NTLA at a glance

Intellia Therapeutics, Inc. (NTLA, SEC CIK 1652130) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Intellia Therapeutics, Inc. (NTLA) reported revenue of $67.7 million (up 16.9% from FY2024) and a net loss of $412.7 million. Diluted EPS was -$3.81.
  • As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Intellia Therapeutics, Inc. (NTLA) shares worth $985.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by LEONARD JOHN M on November 2, 2026 of 9,000 shares at $11.99 per share.
  • In the last 90 days, NTLA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($131K) on Form 4, a net sale of $131K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$67.7M
+16.9% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$131K
13F holders
35 funds
$985.3M · +2 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: biotechnology firm developing CRISPR-based in vivo genome editing therapies targeting severe diseases
  • New emphasis on Phase 3 products lonvo-z and nex-z for hereditary angioedema and transthyretin amyloidosis, with commercial launch preparation for lonvo-z in H1 2027
  • Strategic focus shifted towards advancing first-in-class systemic CRISPR therapies with single IV infusions in outpatient settings
  • Employee count increased with shares issued to 116.3M from 102.0M year-over-year, net loss reduced to $412.7M from $519.0M in 2024
  • Collaboration revenue grew to $67.7M from $57.9M, signaling stronger partner-based funding streams in 2025

Risk Factors

  • Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
  • Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility
  • Operational risk: $195.1M committed lease payments starting mid-2026 for new Cambridge office/lab space could pressure cash flow
  • Competitive risk: reliance on Regeneron collaboration contributing $23.7M in cost reimbursements subject to partnership risks
  • Financial risk: $394.7M net cash used in operating activities in 2025, with runway into H2 2027 excluding milestones or new capital raises

Management Discussion & Analysis

  • No capital allocation information such as buybacks, dividends, or capex mentioned
  • Forward-looking statements referenced but no specific management outlook or guidance included

AI summary of the NTLA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added risk, FDA acceptance of lonvo-z BLA and Priority Review triggered uncertainty for first in vivo CRISPR therapeutic application, with PDUFA date March 10, 2027
  • Most material update, MAGNITUDE and MAGNITUDE-2 clinical holds lifted in first quarter 2026 after Grade 4 liver injury and patient death
  • Regulatory risk, FDA may impose extended follow-up, including a recommended 15-year observation period for genome-editing recipients
  • Legal risk, PTAB again awarded CRISPR eukaryotic patent priority to Broad Institute on March 26, 2026, with UC/Vienna/Charpentier appeal pending
  • Financial risk, September 2026 credit facility permits up to $400 million but requires minimum $50 million liquidity before lonvo-z BLA approval

Management Discussion & Analysis

  • Collaboration revenue $7.2M, down $6.6M YoY from $13.8M
  • Operating loss $122.3M vs $111.5M YoY, net loss $127.5M vs $101.3M
  • Nex-z R&D $21.4M, highest program spend, up $1.5M; lonvo-z $10.2M, down $4.9M
  • Cash, equivalents and marketable securities $614.8M; operating cash outflow $285.9M through nine months
  • Lonvo-z BLA Priority Review, PDUFA date March 10, 2027; planned launch first quarter 2027 if approved

AI summary of the NTLA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor webcast focused on preparing lonvo-z for patients with hereditary angioedema (HAE)
  • Presentation materials furnished as Exhibit 99.1, providing the detailed program update

Item EX-99.1: Item EX-99.1

  • FDA accepted lonvo-z’s BLA with priority review and a March 10, 2027 PDUFA goal, advancing Intellia toward potential commercial launch
  • Phase 3 HAELO met primary and key secondary endpoints, including 62% attack-rate reduction and 87% fewer attack-free weeks versus placebo
Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Investor presentation focused on preparing lonvo-z for patients with hereditary angioedema
  • Event provides an update on commercial readiness and potential launch execution for lonvo-z

Item EX-99.1: Item EX-99.1

  • Lonvo-z BLA accepted with FDA priority review, PDUFA decision target March 10, 2027, accelerating potential commercial launch
  • Phase 3 HAELO met primary and key secondary endpoints, reducing attack rate 62% versus 11% with placebo
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and business updates announced for quarter ended September 30, 2026
  • Full results and operating developments available in Exhibit 99.1, the investor-relevant source for detailed figures and outlook

Item EX-99.1: Item EX-99.1

  • Q3 2026 results support a potential 2027 commercial inflection, with lonvo-z BLA priority review and March 10, 2027 PDUFA date
  • Commercial launch preparation underway, including field organization deployment and payer engagement for a planned first-quarter 2027 launch

AI summaries of NTLA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NTLA

Don't miss the next NTLA filing

  • Alerts as it files. A push when NTLA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NTLA, by share count.
  • Ask anything. An AI agent that reads every NTLA filing and answers with sources.

NTLA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
LEONARD JOHN MSellNov 2, 2026$11.99
Marantz Jing L.AOct 26, 2026-
Marantz Jing L.AOct 26, 2026-
Dube Michael PSellOct 2, 2026$12.43
LEONARD JOHN MSellAug 21, 2026$13.00
LEONARD JOHN MSellAug 20, 2026$12.60
Dulac Edward J IIISellJul 22, 2026$11.25
Dulac Edward J IIISellJul 2, 2026$18.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$57.9M$67.7M
Operating Income--$534.3M-$441.0M
Net Income-$481.2M-$519.0M-$412.7M
Op. Margin--923.1%-651.7%
Net Margin--896.8%-609.9%
Balance Sheet
Total Assets$1.3B$1.2B$842.1M
Equity-$872.0M$671.4M
ROE--59.5%-61.5%
Per Share
EPS$-5.42$-5.25$-3.81
Cash Flow
Operating CF--$348.9M-$394.7M
CapEx$14.0M$5.8M$1.1M

Source: XBRL data in Intellia Therapeutics, Inc. (NTLA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NTLA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NTLA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202635$985.3M
Q2 202633$1.53B
Q1 202631$945.6M
Q4 202530$657.8M
Q3 202531$1.15B
Q2 202530$575.4M
Q1 202525$363.8M
Q4 202422$497.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NTLA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
8-KNov 12, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 3, 2026--
4Oct 28, 2026--
4Oct 6, 2026--
8-KSep 8, 2026Analysis-
8-KSep 4, 2026Analysis-
4Aug 24, 2026--
SC 13GAug 7, 2026-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 24, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
8-KJun 15, 2026Analysis-
4Jun 10, 2026-
4Jun 10, 2026-
8-KJun 10, 2026Analysis
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-

Related Health Care companies

All Health Care →

NTLA SEC filings: frequently asked questions

Are NTLA insiders buying or selling?

In the last 90 days, Intellia Therapeutics, Inc. (NTLA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $131,080 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NTLA stock?

As of September 30, 2026, the largest Intellia Therapeutics, Inc. (NTLA) holders among the 13F filers tracked by SignalX were BlackRock ($193.4 million), ARK Investment Management ($192.1 million), State Street Corp ($94.2 million), Vanguard Portfolio Management LLC ($89.1 million), D.E. Shaw & Co ($73.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NTLA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Intellia Therapeutics, Inc. (NTLA) reported revenue of $67.7 million (up 16.9% from FY2024) and a net loss of $412.7 million. Diluted EPS was -$3.81. The figures come from the XBRL data in the 10-K.

What are the main risks in NTLA's latest 10-K?

In the 10-K filed February 26, 2026, Intellia Therapeutics, Inc. (NTLA) flagged: Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K. Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility. (AI summary of the Risk Factors section.)

What did NTLA report in its latest 8-K?

Intellia Therapeutics, Inc. (NTLA) filed an 8-K on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor webcast focused on preparing lonvo-z for patients with hereditary angioedema (HAE).

What are the latest NTLA SEC filings?

Intellia Therapeutics, Inc. (NTLA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 3, 2026.

What is NTLA's SEC CIK number?

Intellia Therapeutics, Inc. (NTLA)'s SEC Central Index Key (CIK) is 1652130. EDGAR lists every NTLA filing under that number.

Ask anything about NTLA

The research agent reads NTLA's filings, financials, insider trades and 13F holders, then answers with sources.